This week, Big Pharma companies AbbVie, Amgen and Pfizer reported third quarter
earnings that surpassed Wall Street analyst expectations. These strong earnings
come following numerous price hikes from the companies on their best-selling
products throughout the year.





 



BIG PHARMA EARNINGS WATCH: ABBVIE, AMGEN & PFIZER

Major Drug Companies Surpass Wall Street Forecasts as Price Hikes Boost
Earnings



This week, Big Pharma companies AbbVie, Amgen and Pfizer reported third
quarter earnings that surpassed Wall Street analyst expectations. These strong
earnings come following numerous price hikes from the companies on their
best-selling products throughout the year. Several of the companies raised
their guidance for the year. In fact, AbbVie’s CEO, on the company’s earnings
call,said
<[link removed]>
: “We’ve beaten and raised in every quarter in 2025.”



During the Pfizer earnings call
<[link removed]>
, an analyst from Wells Fargo brought up the pricing of GLP-1 drugs in regards
to Pfizer’s bid for obesity drug developer Metsera. In response, Pfizer’s CEO,
Albert Bourla, stated that “competition brings prices down.” Bourla’s comment
is rich given the plethora of anti-competitive tactics Big Pharma companies
like Pfizer utilize to block lower-cost generic and biosimilar alternatives —
driving up prices for patients while padding their own profits — while the
pharmaceutical industry simultaneously opposes market-based solutions to foster
greater competition.



Get a full recap on AbbVie, Amgen and Pfizer’s strong third-quarter earnings
fueled by egregious pricing and anti-competitive practices below.



AbbVie

* AbbVie posted better-than-expected earnings for the third quarter
<[link removed]>
.
* The company’s net revenue grew 9.1 percent to $15.78 billion
<[link removed]>
, beating Wall Street expectations.
* AbbVie’s blockbuster psoriasis drug Skyrizi brought in $4.7 billion
<[link removed]>
, up 47 percent year over year.
* Meanwhile, the company’s arthritis drug Rinvoq brought in an additional
$2.2 billion
<[link removed]>
, up 35 percent year over year.
* AbbVie reported growth across its immunology and neuroscience portfolios,
with revenue increasing12 percent and 20 percent
<[link removed]>
, respectively.
Amgen

* Amgen also reported third quarter earnings that topped analysts’ estimates
<[link removed]>
.
* The company’s third quarter revenue grew 12 percent to $9.56 billion
<[link removed]>
, beating expectations.
* Amgen’s product sales rose 12 percent
<[link removed]>
, with osteoporosis drug Prolia seeing anine percent increase
<[link removed]>
year over year.
* The Big Pharma giant also raised
<[link removed]>
its outlook for the full year.
Pfizer

* Pfizer also reported earnings that beat Wall Street expectations
<[link removed]>.
* The company also reported
<[link removed]> revenue that
topped expectations and raised its profit guidance for the year.
* The Big Pharma company’s revenue rose to $16.7 billion
<[link removed]>
, surpassing Wall Street estimates.
* The company’s blood thinner drug Eliquis brought in $2 billion
<[link removed]>
, up 22 percent from the same quarter last year.
The companies’ strong third quarter earnings come after they have engaged in
price hikes across their portfolios earlier this year.



AbbVie

* So far in 2025, AbbVie has hiked prices on 17 prescription drugs
<[link removed]>, including Skyrizi by 4.1
percent and Rinvoq by five percent.
* AbbVie increased prices on 19 prescription drugs in 2024
<[link removed]>, including a 5.8 percent price
increase on Skyrizi and five percent increase on Rinvoq.
* AbbVie hiked prices on 40 prescription drugs
<[link removed]> in January 2023, including
eight percent <[link removed]> increases each on
the company’s blockbuster autoimmune drugs Skyrizi and Rinvoq.
* In 2022, AbbVie increased prices on more than 40 prescription drugs
<[link removed]>.
Amgen

* This year, Amgen has hiked prices for 23 prescription drugs
<[link removed]> by an average of five percent.
* Last year, Amgen raised prices on 36 prescription drugs
<[link removed]>, including a 6.9 percent
increase on osteoporosis treatment Prolia as well as five percent price
increases on autoimmune drugs Enbrel and Otezla.
* In 2023, Amgen raised prices on more than 20
<[link removed]> prescription drugs, including
on osteoporosis treatment Prolia and autoimmune drug Otezla by5.9 percent
<[link removed]> each.
Pfizer

* Since January 2025, Pfizer has hiked prices on 90 prescription drugs.
<[link removed]>
* Pfizer hiked prices on more than 100 prescription drugs
<[link removed]> in 2024.
* In 2024, price hikes included a six percent
<[link removed]>
increase on breast cancer drug IBRANCE, aseven percent
<[link removed]>
increase on cardiomyopathy drug Vyndaqel, and a4.9 percent
<[link removed]>
increase on arthritis drug Xeljanz.
* In 2023, Pfizer hiked drug prices on more than 120 medications
<[link removed]>
, and in 2022, the company hiked prices on more than160 prescriptions
<[link removed]>
in their portfolio.
Read more on expectation-beating third quarter earnings from Johnson & Johnson
HERE <[link removed]>.



Read more on GSK, Merck, Bristol Myers Squibb, Eli Lilly and Gilead’s third
quarter earningsHERE
<[link removed]>
.



And stay tuned as we continue to monitor third quarter earnings calls from
brand name drug companies this week.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>